August 1, 2011 — 12:11pm ET By Tracy Staton
The Merck drug has come up against the obstacles most had expected--chiefly
dosing issues. "Merck acknowledged that Victrelis's complicated dosing has been
an issue for physicians," Wells Fargo's Brian Abrahams told clients. "The better
profile and simpler dosing of Incivek provide important practical advantages for
Vertex."
"By any measurement, Vertex is winning the market share battle
meaningfully, but everyone needs to agree it's still early days," R.W. Baird
analyst Thomas Russo said (as quoted by The Street). Morningstar's Damien
Conover agreed that the contrast isn't completely clear. "People are trying to
gauge the split of the market...and we don't know what's happening." Yet.
Read more: Merck: Don't declare a hep C victor yet - FiercePharma http://www.fiercepharma.com/story/merck-dont-declare-hep-c-victor-yet/2011-08-01#ixzz1TnQCMQX6
- read the Bloomberg story- get more from The Street
No comments:
Post a Comment